Meeting the FDA's CAPA Expectations

Year after year, findings of insufficient corrective and preventative action (CAPA) procedures have topped the list of the most common observations found during FDA inspections within the medical device industry.
To stay in compliance, avoid receiving a 483 citation, and keep a safe product on the market, medical device companies' leadership teams must understand CAPA and take steps to meet the FDA's expectations relating to CAPA.
There are times when it's valuable to have a third-party expert on your team, such as when working on establishing and improving your CAPA procedures. If you have concerns about the status or quality of your CAPA procedures, or just want to learn more about CAPA, download our white paper to learn how to be CAPA-ready.
Whitepapers

Share

Infographic

The Cost of Poor Project Management

Project Management isn’t for the faint of heart. There is a shockingly high rate of project failure… but on the other hand, great project management can be a key differentiator that leads a company...

Webinar

Free Webinar: Effective FDA Engagement

FDA faces challenges (like new technology) and new review models (like real world evidence) that stretch agency standards and practices. At the same time, imperatives like product safety and efficacy...

Infographic

Successfully Passing MHRA Inspections for Overseas Manufacturing Sites

ProPharma Group offers GMP and GDP compliance services from clinical development to commercial distribution of the products' lifecycle. ProPharma Group’s Compliance and Quality team completed the...